

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Foresite Capital Management IV, LLC</u> <hr/> (Last) (First) (Middle) 600 MONTGOMERY STREET SUITE 4500 <hr/> (Street) SAN FRANCISCO CA 94111 <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>Kinnate Biopharma Inc. [ KNTE ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) 12/07/2020					
			4. If Amendment, Date of Original Filed (Month/Day/Year)					
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person					

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/07/2020		C		9,171,643	A	\$0.00	9,671,643	I	See Footnote <sup>(1)</sup>
Common Stock	12/07/2020		C		500,001	A	\$0.00	875,001	I	See Footnote <sup>(2)</sup>
Common Stock	12/07/2020		C		166,667	A	\$0.00	291,667	I	See Footnote <sup>(3)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(4)	12/07/2020		C		6,347,893		(4)	(4)	Common Stock	6,347,893	\$0.00	0	I	See Footnote <sup>(1)</sup>
Series A Preferred Stock	(4)	12/07/2020		C		298,465		(4)	(4)	Common Stock	298,465	\$0.00	0	I	See Footnote <sup>(1)</sup>
Series A Preferred Stock	(4)	12/07/2020		C		99,488		(4)	(4)	Common Stock	99,488	\$0.00	0	I	See Footnote <sup>(1)</sup>
Series B Preferred Stock	(5)	12/07/2020		C		2,666,002		(5)	(5)	Common Stock	2,666,002	\$0.00	0	I	See Footnote <sup>(2)</sup>
Series B Preferred Stock	(5)	12/07/2020		C		55,922		(5)	(5)	Common Stock	55,922	\$0.00	0	I	See Footnote <sup>(2)</sup>
Series B Preferred Stock	(5)	12/07/2020		C		18,641		(5)	(5)	Common Stock	18,641	\$0.00	0	I	See Footnote <sup>(2)</sup>
Series C Preferred Stock	(6)	12/07/2020		C		157,222		(6)	(6)	Common Stock	157,748	\$0.00	0	I	See Footnote <sup>(3)</sup>
Series C Preferred Stock	(6)	12/07/2020		C		145,128		(6)	(6)	Common Stock	145,614	\$0.00	0	I	See Footnote <sup>(3)</sup>
Series C Preferred Stock	(6)	12/07/2020		C		48,376		(6)	(6)	Common Stock	48,538	\$0.00	0	I	See Footnote <sup>(3)</sup>

1. Name and Address of Reporting Person\*  
Foresite Capital Management IV, LLC  


---

 (Last) (First) (Middle)  
 600 MONTGOMERY STREET  
 SUITE 4500  


---

 (Street)  
 SAN FRANCISCO CA 94111

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Foresite Capital Fund IV, L.P.</a>		
(Last)	(First)	(Middle)
600 MONTGOMERY STREET SUITE 4500		
(Street)		
SAN FRANCISCO CA 94111		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Foresite Capital Management V, LLC</a>		
(Last)	(First)	(Middle)
600 MONTGOMERY STREET SUITE 4500		
(Street)		
SAN FRANCISCO CA 94111		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Foresite Capital Fund V, L.P.</a>		
(Last)	(First)	(Middle)
600 MONTGOMERY STREET SUITE 4500		
(Street)		
SAN FRANCISCO CA 94111		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Foresite Capital Opportunity Management V, LLC</a>		
(Last)	(First)	(Middle)
600 MONTGOMERY STREET SUITE 4500		
(Street)		
SAN FRANCISCO CA 94111		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Foresite Capital Opportunity Fund V, L.P.</a>		
(Last)	(First)	(Middle)
600 MONTGOMERY STREET SUITE 4500		
(Street)		
SAN FRANCISCO CA 94111		
(City)	(State)	(Zip)

**Explanation of Responses:**

- The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
- Each share of the issuer's Series A Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.
- Each share of the issuer's Series B Preferred Stock automatically converted into one share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.
- Each share of the issuer's Series C Preferred Stock automatically converted into 1.00335008 share of Common Stock immediately prior to the completion of the issuer's public offering and had no expiration date.

**Remarks:**

This Form 4 is one of two Form 4s filed on the date hereof in respect of these transactions. The Reporting Person for the other Form 4 is James B. Tananbaum.

